Niagen Bioscience, Inc. reported second quarter 2026 financial results with net sales of $29.8 million, including $24.2 million from Tru Niagen, and a gross margin of 64.8%. The company generated net income of $1.0 million (diluted EPS of $0.01) and adjusted EBITDA of $3.0 million. Operating cash flow for the first half of 2026 was $1.6 million, ending with $66.7 million in cash and no debt. The company repurchased $2.8 million of common stock during the quarter. Strategically, Niagen launched its Niagen Plus telehealth platform and introduced NB4168, a proprietary therapeutic candidate for rare genetic diseases, which received Rare Pediatric Disease designation from the FDA. The firm operates in the bioscience sector, focusing on NAD+ precursors for healthy aging supplements and pharmaceutical development.